Diltiazem Hydrochloride Capsule, Extended Release
Product Images NDC 71335-1776

Product Visual Gallery

This gallery contains 3 technical images submitted to the FDA as part of the official labeling for Diltiazem Hydrochloride (NDC 71335-1776). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Bryant Ranch Prepack, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Image (Image 01)

Chemical structure of diltiazem hydrochloride showing its molecular framework with aromatic rings, methoxy group, and hydrochloride component.*

FDA Label Image

Image (Image 02)

Data table presenting adverse reaction rates from placebo-controlled trials comparing diltiazem hydrochloride extended-release capsules to placebo for angina and hypertension. The table lists headache, dizziness, bradycardia, AV block first degree, edema, and asthenia, with corresponding percentages for 607 patients receiving diltiazem hydrochloride and 301 receiving placebo.*

FDA Label Image

Label (Lbl713351776)

Label for diltiazem hydrochloride extended-release 180 mg capsules by Bryant Ranch Prepack. The label states the product is comparable to Cardizem CD 180 mg capsules from Novast Laboratories. It includes storage instructions to keep at 20-25°C (68-77°F) and keep out of reach of children. The package size shown is 30 capsules, with NDC 71335-1776-1 and a barcode.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.